CD20 Positive

11 registered clinical trials studyying CD20 Positive.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphom NCT04007029	Jonsson Comprehensive Cancer Center	Phase 1
Active Not Recruiting	Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma NCT03946878	M.D. Anderson Cancer Center	Phase 2
Suspended	Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma NCT03704714	Northwestern University	Phase 1 / Phase 2
Completed	Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage NCT02532257	M.D. Anderson Cancer Center	Phase 2
Completed	Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell L NCT02219737	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractor NCT01959698	Roswell Park Cancer Institute	Phase 1
Active Not Recruiting	Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patient NCT01880567	M.D. Anderson Cancer Center	Phase 2
Completed	Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma NCT01729806	National Cancer Institute (NCI)	Phase 1
Completed	Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblasti NCT01363128	M.D. Anderson Cancer Center	Phase 2
Completed	Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell T NCT00880815	M.D. Anderson Cancer Center	Phase 1
Completed	Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplan NCT00439556	M.D. Anderson Cancer Center	Phase 2